Merck KGaA Forecasts Earnings, Sales Growth
Merck, Keytruda and Cancer Drug
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...
Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...
Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...
A sinus infection, known as sinusitis, is one of the most common medical conditions. But in some cases, it can come with dangerous complications.
The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback